The Dow Chemical Company, Midland, MI, USA.
Charles River Laboratories, Den Bosch, The Netherlands.
Crit Rev Toxicol. 2021 Apr;51(4):328-358. doi: 10.1080/10408444.2021.1910625. Epub 2021 Jun 2.
The current understanding of thyroid-related adverse outcome pathways (AOPs) with adverse neurodevelopmental outcomes in mammals has been reviewed. This served to establish if standard rodent toxicity test methods and assays allow identifying thyroid-related modes-of-action potentially leading to adverse neurodevelopmental outcomes, and the human relevance of effects - in line with the European Commission's Endocrine Disruptor Criteria. The underlying hypothesis is that an understanding of the key events of relevant AOPs provides insight into differences in incidence, magnitude, or species sensitivity of adverse outcomes. The rodent studies include measurements of serum thyroid hormones, thyroid gland pathology and neurodevelopmental assessments, but do not directly inform on specific modes-of-action. Opportunities to address additional non-routine parameters reflecting critical events of AOPs in toxicological assessments are presented. These parameters appear relevant to support the identification of specific thyroid-related modes-of-action, provided that prevailing technical limitations are overcome. Current understanding of quantitative key event relationships is often weak, but would be needed to determine if the triggering of a molecular initiating event will ultimately result in an adverse outcome. Also, significant species differences in all processes related to thyroid hormone signalling are evident, but the biological implications thereof (including human relevance) are often unknown. In conclusion, careful consideration of the measurement (e.g. timing, method) and interpretation of additional non-routine parameters is warranted. These findings will be used in a subsequent paper to propose a testing strategy to identify if a substance may elicit maternal thyroid hormone imbalance and potentially also neurodevelopmental effects in the progeny.
目前已经对哺乳动物中与甲状腺相关的不良结局途径(AOPs)和不良神经发育结局进行了综述。这有助于确定标准的啮齿动物毒性测试方法和检测是否可以识别出可能导致不良神经发育结局的与甲状腺相关的作用模式,以及与欧洲委员会内分泌干扰物标准相一致的效应的人类相关性。基本假设是,对相关 AOP 的关键事件的理解提供了对不良结局的发生率、幅度或物种敏感性差异的深入了解。啮齿动物研究包括血清甲状腺激素、甲状腺病理学和神经发育评估的测量,但不能直接提供特定作用模式的信息。提出了在毒理学评估中解决反映 AOP 关键事件的其他非常规参数的机会。这些参数似乎与支持特定与甲状腺相关的作用模式的识别有关,前提是克服了当前的技术限制。目前对定量关键事件关系的理解通常很薄弱,但需要确定分子起始事件的触发是否最终会导致不良结局。此外,与甲状腺激素信号相关的所有过程中都存在明显的物种差异,但这些过程的生物学意义(包括人类相关性)通常是未知的。总之,需要仔细考虑额外非常规参数的测量(例如时间、方法)和解释。这些发现将在随后的一篇论文中使用,以提出一种测试策略,以确定一种物质是否会引起母体甲状腺激素失衡,并可能对后代产生神经发育影响。